Highest development stage: Phase 1

Development status: Discontinued

Combination therapy

Mechanism of Action/Target pathogen: Disrupts the outer membrane by direct interaction with the lipid A component of the LPS and and disrupts the physical integrity of the phospholipid bilayer of the inner membrane, and possibly additional modes of action.

Reason dropped: Replaced by SPR206; develoiped instead as an antibiotic adjuvant

Additional information: Potentiates the activity of rifampin, clarithromycin, azithromycin, mupirocin, fusidic acid and vancomycin against E. coli, K. pneumoniae and A. baumannii but not P. aeruginosa.